2 weeks Ago By ABMN Staff
Lynx1 Capital Management LP grew its position in GH Research PLC ( NASDAQ:GHRS – Free Report ) by 19.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,966,726 shares of the company’s stock after purchasing an additional 656,163 shares during the period.
GH Research makes up approximately 16.7% of Lynx1 Capital Management LP’s holdings, making the stock its 3rd biggest position. Lynx1 Capital Management LP owned 7.
62% of GH Research worth $46,252,000 at the end of the most recent quarter. Several other institutional investors and hedge funds also recently modified their holdings of the business. AdvisorShares Investments LLC lifted its position in GH Research by 4.
3% in the fourth quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock worth $280,000 after purchasing an additional 1,977 shares during the period. RA Capital Management L.
P. lifted its holdings in shares of GH Research by 11.9% in the first quarter.
RA Capital Management L.P. now owns 6,251,714 shares of the company’s stock valued at $66,643,000 after buying an additional 664,381 shares during the period.
Finally, BVF Inc. IL lifted its holdings in shares of GH Research by 12.1% in the fourth quarter.
BVF Inc. IL now owns 10,400,158 shares of the company’s stock valued at $60,321,000 after buying an additional 1,125,000 shares during the period. Institutional investors own 56.
90% of the company’s stock. GH Research Stock Performance NASDAQ GHRS opened at $7.00 on Friday.
The firm’s 50 day moving average price is $10.02 and its two-hundred day moving average price is $11.14.
GH Research PLC has a twelve month low of $5.05 and a twelve month high of $14.99.
The stock has a market cap of $364.20 million, a price-to-earnings ratio of -11.29 and a beta of 0.
83. Analyst Ratings Changes GHRS has been the subject of several research reports. JMP Securities restated a “market outperform” rating and set a $39.
00 price objective on shares of GH Research in a research report on Wednesday, September 4th. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of GH Research in a report on Thursday, September 5th.
Check Out Our Latest Report on GH Research GH Research Company Profile ( Free Report ) GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Further Reading Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.
com's FREE daily email newsletter ..
